Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2023
Pembrolizumab with trastuzumab and chemotherapy for the first-line treatment of patients with advanced HER2 positive gastric or gastro-oesophageal junction cancer
1 December 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Cabozantinib maleate with nivolumab for patients with untreated advanced renal cell carcinoma
30 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Idecabtagene vicleucel for the treatment of patients with relapsed and refractory multiple myeloma after 3 or more treatments
30 November 2023 - NICE is unable to make a recommendation on the use of idecabtagene vicleucel (Abecma) for the treatment ...
Posted by Michael Wonder on 29 Nov 2023
Belzutifan for the treatment of patients with a tumour associated with von Hippel-Lindau disease
29 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2023
Tisagenlecleucel for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
29 November 2023 - NICE is unable to make a recommendation on the use of tisagenlecleucel (Kymriah) for the treatment of ...
Posted by Michael Wonder on 23 Nov 2023
Cedazuridine with decitabine for patients with untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
23 November 2023 - NICE is unable to make a recommendation on the use of cedazuridine with decitabine (Inaqovi) for the ...
Posted by Michael Wonder on 22 Nov 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia (final guidance)
22 November 2023 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 15 Nov 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with metastatic PSMA positive hormone-relapsed prostate cancer after two or more treatments
15 November 2023 - NICE has published final evidence-based recommendations on the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) ...
Posted by Michael Wonder on 02 Nov 2023
Ivosidenib for the treatment of patients with advanced IDH1 mutation positive cholangiocarcinoma after at least one line of treatment
2 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Nov 2023
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
1 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Nov 2023
Cabozantinib maleate for previously treated adults with advanced differentiated thyroid cancer that is unsuitable for or refractory to radioactive iodine
1 November 2023 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) for previously treated ...
Posted by Michael Wonder on 25 Oct 2023
Daratumumab in combination with lenalidomide and dexamethasone for untreated patients with multiple myeloma who are ineligible for stem cell transplantation
25 October 2023 - NICE has published final evidence-based recommendations on the use of daratumumab (Darzalex) in combination with lenalidomide ...
Posted by Michael Wonder on 24 Oct 2023
Abiraterone: thousands of men miss out on life-extending prostate cancer drug
24 October 2023 - Thousands of patients in England and Northern Ireland are missing out on a life-extending prostate cancer ...
Posted by Michael Wonder on 21 Oct 2023
Brukinsa receives positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukaemia
20 October 2023 - BeiGene today announced that NICE of the United Kingdom has issued a final draft guidance recommending ...
Posted by Michael Wonder on 19 Oct 2023
Tabelecleucel for the treatment of patients with a post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus
19 October 2023 - NICE is unable to make a recommendation on the use of tabelecleucel (Ebvallo) for the treatment of ...